

## Evaluation of the Effectiveness of Tenofovir in Chronic Hepatitis B Patients

Seval Müzeyyen Ecin<sup>1,\*</sup>, [MD]

ORCID:0000-0002-7701-7826

Nursel Çalık Başaran<sup>2</sup>, [MD]

ORCID:0000-0002-1290-6905

Murat Aladağ<sup>3</sup>, [MD]

ORCID:0000-0002-4563-7027

<sup>1</sup>Hacettepe University, Faculty of Medicine, Department of Internal Medicine, Unit of Occupational Medicine, Ankara, Turkey.

<sup>2</sup>Hacettepe University, Faculty of Medicine, Department of Internal Medicine, Division of General Internal Medicine, Ankara, Turkey

<sup>3</sup>Inonu University, Faculty of Medicine, Department of Internal Medicine, Division of Gastroenterology, Malatya, Turkey

Corresponding Author: Seval Müzeyyen Ecin.

Hacettepe University, Faculty of Medicine, Department of Internal Medicine, Unit of Occupational Medicine, Ankara, Turkey

e-mail: muzeyyenecin@hacettepe.edu.tr

Phone: +90 312 305 34 26

DOI: 10.32552/0.ActaMedica.423

Received: 14 December 2019, Accepted: 03 March 2020,

Published online: 20 March 2020

### ABSTRACT

**Objectives:** HBV infection is a global public health problem. Tenofovir disoproxil fumarate and tenofovir alafenamide are nucleotide reverse transcriptase inhibitors and used for the treatment of chronic Hepatitis B infection. The aim of this study was to evaluate treatment response and efficacy of Tenofovir disoproxil fumarate. **Materials and Methods:** The study included hepatitis B positive patients who started to use Tenofovir disoproxil fumarate. We retrospectively reviewed electronic medical files of Hepatitis B patients. Hepatitis B surface antigen, Hepatitis B surface antibody, Hepatitis B e antigens, Hepatitis B e antibody, Hepatitis B viral DNA, aspartate aminotransferase, alanine aminotransferase values were evaluated in the 1<sup>st</sup>, 3<sup>rd</sup>, 6<sup>th</sup>, 9<sup>th</sup>, and 12<sup>th</sup> months.

**Result:** None of the patients under Tenofovir disoproxil fumarate treatment was "primary resistant". Alanine aminotransferase normalization at 12<sup>th</sup> month was seen in 80.4% of study population. Hepatitis B surface antigen seroconversion was detected only in one patient (0.85%) at 9<sup>th</sup> months and Hepatitis B e antigen seroconversion was observed in 9 patients (8.3%) under Tenofovir disoproxil fumarate treatment. At the sixth month of Tenofovir disoproxil fumarate treatment, complete response was found in 77 (65.8%), partial response in 21 (18%) and inadequate response were in 19 (16.2%). Among Hepatitis B e antigen positive patients, 44 (80 %) patients had undetectable Hepatitis B virus DNA levels at the end of 12<sup>th</sup> month and among Hepatitis B e antigens negative patients, 52 (91.2%) patients had undetectable Hepatitis B DNA levels at the end of 12<sup>th</sup> month ( $p < 0.01$ ).

**Conclusion:** Among patients with chronic HBV infection, Tenofovir disoproxil fumarate had satisfying antiviral efficacy. There is no primary resistance in patients treated with Tenofovir disoproxil fumarate. Patients had statistically significant improvement in aspartate aminotransferase, alanine aminotransferase, Hepatitis B virus DNA levels.

**Key words:** Chronic Hepatitis B, tenofovir, treatment

## INTRODUCTION

Hepatitis B virus (HBV) is a double-stranded DNA virus, family of hepadna viruses. HBV infection is a global public health problem. It is estimated that there are more than 250 million HBV infected patients in the world, of whom approximately 600,000 die annually from HBV-related liver disease [1]. Chronic hepatitis B (CHB) is endemic at sub-Saharan Africa and the Asia/Pacific where the

infection transmitted through perinatally or horizontally during early childhood. In Western countries, HBV spreads through high risk sexual behavior, injection drug use and exposure to blood product [2,3]. The likelihood of liver failure from acute HBV is less than 1 percent, and in immunocompetent adults, the likelihood of progression to chronic HBV infection is less than 5 percent [4]. Diagnosis of CHB

is based upon the persistence of hepatitis B surface antigen (HBsAg) for at least six months [5]. Serum HBV DNA levels are important predicting the development of cirrhosis and hepatocellular carcinoma (HCC) [6]. The overall goal of treatment for CHB is to prevent or reduce the development of cirrhosis, end-stage liver disease, HCC and death. Short-term goals of the treatment are viral suppression, normalization of ALT, absence of viral resistance, hepatitis B e antigen (HBeAg) loss, and seroconversion, hepatitis B surface antigen (HBsAg) loss, and seroconversion, and improvement in liver histology [7]. CHB treatment are currently based on HBeAg status, HBV DNA levels and ALT levels. Patients with CHB are initially classified as having either HBeAg-positive or HBeAg-negative. There are seven agents currently available for the treatment: interferon alfa-2b, peginterferon alfa-2a, lamivudine, entecavir, telbivudine, adefovir, tenofovir [7].

Tenofovir disoproxil fumarate (TDF) and tenofovir alafenamide (TAF) are nucleotide reverse transcriptase inhibitors (NRTIs) that are used for the treatment of CHB infection. TDF is an acyclic nucleotide diester analog of adenosine monophosphate, which is administered orally as the prodrug TDF (300 mg daily) or TAF (25 mg daily). TDF can be used as first-line therapy in treatment or in those who have had prior exposure, or developed drug resistance, to other nucleos(t)ide analogues [8].

The aim of this study was to evaluate the treatment response and efficacy of TDF, which was a new treatment regimen in Turkey at that time period.

## MATERIALS and METHODS

This descriptive, retrospective study was conducted between January 2009 and January 2011 at Inonu University Faculty, Turgut Ozal Medicine Center, Department of Internal Medicine, Division of Hepatology Outpatient Clinic. We included hepatitis B positive patients who used TDF. Treatment naïve as well as treatment experienced patients were included in this study. We retrospectively reviewed the electronic medical files of CHB patients. HBsAg, Hepatitis B surface antibody (Anti-HBsAb),

HBeAg, Hepatitis B e antibody (Anti-HBeAb), HBV-DNA, 1<sup>st</sup>, 3<sup>rd</sup>, 6<sup>th</sup>, 9<sup>th</sup> and 12<sup>th</sup> aspartate aminotransferase (AST), alanine aminotransferase (ALT) values were evaluated in the 1, 3., 6., 9., and 12. months. The patients with decompensated cirrhosis, liver disease due to another cause, HIV infection, previous organ transplantation, decompensated cardiovascular disease, uncontrolled psychiatric or convulsive diseases, uncontrolled hemoglobinopathies and hemophilia, autoimmune disease, abnormal serum creatinine values, cytopenia (hemoglobin < 12 g / dl, leukocyte count < 3500 / mm<sup>3</sup>, neutrophil count < 1500 / mm<sup>3</sup>, platelet count < 100000 / mm<sup>3</sup>), positive autoantibodies (antinuclear antibodies (ANA), anti-mitochondrial antibodies (AMA), Anti-smooth muscle antibodies (ASMA), Anti-liver-kidney microsomal-1 (ALKM-1)) were excluded from the study.

### 3<sup>rd</sup> and 6<sup>th</sup> month Evaluation of Treatment Results

Indicators of the effectiveness of treatment are suppression of HBV DNA and loss of hepatitis B e antigen (HBeAg) (in patients who were initially HBeAg positive) and followed by loss of hepatitis B surface antigen (HBsAg) Virologic response can be classified as complete, partial, or inadequate according to viral DNA change at the end of 24 weeks of therapy. Complete virologic response was defined as HBV DNA levels <60 IU/ml (<300 copies/ml), which is the lower limit of detection of standard PCR assays, while a partial virologic response was defined as residual HBV DNA levels less than 2,000 IU/ml (<4 log<sub>10</sub> copies/ml) at week 24. Inadequate virologic responses were defined as residual HBV DNA levels of ≥2,000 IU/ml (≥4 log<sub>10</sub> copies/ml) at week 24 [9].

Primary resistance was accepted if serum HBV DNA concentration was not reduced by at least 1 log<sub>10</sub> in the end of 3 months of treatment. HBV DNA was studied with Rotor-Gene 6000 Real-Time PCR and Arthus HBVRG-DNA kit.

Rights and privacy of patients were protected. Ethical approval is not available, as this study is a retrospective study completed in 2011. The study was carried out in accordance with the Declaration of Helsinki and its amendments.

### Statistical analysis

Data were analyzed using IBM SPSS Statistics for

Windows, version 21.0 (IBM Corp., Armonk, NY, USA). Descriptive statistics of continuous variables with normal distributions were given as means  $\pm$  standard deviation whereas those without normal distributions were given as median and minimum-maximum range. Wilcoxon signed-rank test and Mc Nemar's test were used to compare two or more dependent variables. P-values below 0.05 were considered statistically significant.

## RESULTS

We included 117 HBV- positive patients using TDF between 2009-2011 years. The mean age was  $42.0 \pm$

14.6 years and 77 (65.8%) were male. Distribution of AST, ALT, HBV DNA values in 1<sup>st</sup>, 3<sup>rd</sup>, 6<sup>th</sup>, 9<sup>th</sup> and 12<sup>th</sup> month were given in Table 1. The median ALT values were 59.8 (15-873) U/L in the 1st month of treatment (ALT normal range 10 to 40 units/L) [10]. ALT normalization at 12th month was seen in 80.4% of study population. The change of AST, ALT, HBV DNA values from 1st to 12th month were statistically significant ( $p < 0.05$ ). HBV DNA were positive in all 117 patients at the beginning of treatment. In the 3<sup>rd</sup> month of treatment, all patients had  $>1 \log_{10}$  decrease in HBV DNA, so none of the patients under TDF treatment were "primary resistant."

Table 1. Distribution of AST, ALT, HBV DNA values 1st, 3rd, 6th, 9th and 12th month

	AST units/L (median (min-max))	ALT units/L (median (min-max))	HBV DNA IU/ml (median (min-max))
1 <sup>st</sup> month	36 (15-873)	46 (13-796)	124x10 <sup>3</sup> (0-12x10 <sup>9</sup> )
3 <sup>rd</sup> month	28 (15-511)	35(12-249)	1544 (0-34000747)
6 <sup>th</sup> month	28 (14-386)	33 (11-377)	41.5 (0-9x10 <sup>6</sup> )
9 <sup>th</sup> month	25 (10-147)	27(9-134)	0 (0-3x10 <sup>6</sup> )
12 <sup>th</sup> month	25 (14-105)	22 (11-129)	0 (0-2000387)
P* values	<0.05	<0.05	<0.05

\* Decline values of AST, ALT, HBV DNA from 1. to 12. months were compared by using Wilcoxon signed-rank test

HBV DNA levels of HBeAg positive and HBeAg negative patients are given Table 2.

Table 1. Distribution of AST, ALT, HBV DNA values 1st, 3rd, 6th, 9th and 12th month

	HBV DNA IU/ml (median (min-max))	
	HBeAg Positive	HBeAg Negative
1 <sup>st</sup> month	10x10 <sup>5</sup> (0-12x10)	7x10 <sup>4</sup> (0-28x10 <sup>7</sup> )
3 <sup>rd</sup> month	11209 (0-34x10 <sup>6</sup> )	166 (0-10x10 <sup>5</sup> )
6 <sup>th</sup> month	1478 (0-9x10 <sup>6</sup> )	0 (0-85x10 <sup>4</sup> )
9 <sup>th</sup> month	435 (0-3x10 <sup>9</sup> )	0 (0-24x10 <sup>4</sup> )
12 <sup>th</sup> month	0(0-10x10 <sup>5</sup> )	0 (0-20x10 <sup>4</sup> )
P* values	<0.05	<0.05

\*Decline values of HBV DNA from 1. to 12. months were compared by using Wilcoxon signed-rank test

HBsAg seroconversion were detected only in one patient (0.85%) at 9th months of TDF treatment. HBeAg loss were observed in 8 (7.8 %) of the

patients, HBeAg seroconversion were observed in 9 (8.3%) of the patients. Data about HBsAg, and HBeAg seroconversion are given Table 3.

Table 3. Presence and seroconversion of HBsAg, Anti-HBs Ab, HB eAg, Anti-HBe in patients under TDF, by months.

	1 st month N (%)	3 <sup>rd</sup> month N (%)	6 th month N (%)	9 th month N (%)	12 th mont N (%)
HBsAg seroconversion	HBsAg (+): 117 (0)	0 (0)	0 (0)	1 (0.85)	1 (0.85)
HBeAg *					
Positive	55(49.1)				
Negative	57 (50.9)	4 (3.6)	6 (5.4)	6 (5.4)	8 (7.1)
HBeAg lost					

\*Only 112 patients had HBeAg and Anti-HBeAb values.

In the means of viral response, at the sixth month of TDF treatment, complete response was found in 77 (65.8%), partial response in 21 (18%) and inadequate response were in 19 (16.2%).

Among HBeAg positive patients, 44 (80 %) patients had undetectable HBV DNA levels at the end of 12<sup>th</sup> month and among HBeAg negative patients, 52 (91.2%) patients had undetectable HBV DNA levels at the end of 12th month ( $p<0.01$ ).

## DISCUSSION

Here, ALT normalization among CHB patients treated with TDF for 6 and 12 months were achieved by we found that among 117 HBV patients who were treated with TDF, 12<sup>th</sup> month ALT normalization was seen in 80.4%, at the end of 6th month 65.8% of the patients achieved complete response, only 16.2% had inadequate viral response at the end of 6 months. 96 (82.1%) patients had undetectable HBV DNA levels at the end of 12 months. We found that none of the 117 patients under TDF treatment were "primary resistant"

The mean age of HBV positive patients under TDF treatment was  $42.0 \pm 14.6$  years and 77 (65.8%) were male. According to literature, in adult population the prevalence is higher in males and mean age differ in between 25-54 [11].

Serum alanine aminotransferase (ALT) level is an easily accessible surrogate marker for the presence or absence of disease activity of the liver and ALT normalization is used as a short-term goal for treatment [6,7]. In our study ALT normalization at 12th month was 80.4% in patients receiving TDF. Guzelbulut et

al, Başarır et al and Demir et al. found ALT normalizations 85% vs 80%, 83% respectively [12-14].

The efficacy of CHB treatment is followed with ALT, HBV DNA levels, and HBe Ag status [7]. This study showed nearly 4/5 of the patients achieved ALT targets and two thirds of the patients had complete viral remission under TDF. Woo et al. reported that complete remission was seen in 88% of HBV patients under TDF in European and American population. In Turkey Guzelbulut et al., and Başarır et al. found 75% of patients had complete remission under TDF, and those studies were undertaken at the same time period of our study. The reason for the lower rate of complete remission and some patients had still high HBV DNA levels at the end of 12-month treatment in our study can be explained by the lower number of patients and inappropriate drug usage of the patients. As this was a retrospective study, we could not evaluate the drug compliance of the patients. According to first month results, all patients had  $>1$ log decrease in HBV DNA levels, and we did not think about primer drug resistance. HBe Ag status of the patients were important in the treatment response. In other studies, TDF showed the higher effects of inducing undetectable levels of HBV DNA in HBeAg-negative patients. We found that more patients had undetectable HBV DNA levels at the end of 12 month of treatment who were HBeAg negative than HBeAg positive (52; 91.2% vs. 44;80 %, respectively,  $p<0.01$ ). The difference in treatment response was similar the literature [13-16].

In this study, HBeAg loss was observed in 8 (7.8%) and HBeAg seroconversion was observed in 9

(8.3%) patients under TDF. Compared to other studies HBeAg seroconversion were between 20-33% [13-16]. Only one (0.85%) patient had HBsAg loss and seroconversion in our study [5,15,16]. Previous studies showed that HBsAg loss/seroconversion were between 5-8% of the patients under TDF. This difference can be explained by the small sample size, and drug compliance.

The decision to initiate treatment is primarily based upon the presence or absence of cirrhosis, the ALT level, and the HBV DNA level. The immune active phase is when a patient has an ALT level greater than the upper limit of normal in combination with a high HBV DNA level (>2000IU/mL if negative for HBeAg or >20000IU/mL if positive for HBeAg), or if a patient has evidence of at least moderate liver inflammation or fibrosis. Treatment strategies for chronic HBV typically include pegylated interferon (Peg-IFN) or nucleos(t)ide analogs (e.g., entecavir and TDF) [17]. Patients with cirrhosis should be treated regardless of ALT level and at any detectable level of HBV DNA. After our study, more researches had showed the side effects of TDF in the means of renal insufficiency, renal tubular dysfunction, and decreased bone density other side effects. So that most patients were recommended TDF alafenamide, particularly in older patients and those with risk factors for renal impairment or osteoporosis [18]. Inkaya et al. aimed to determine the effects of Tumor necrosis alpha promoter polymorphisms on interferon related side effects during interferon alpha 2b treatment in CHB [19]. Further studies needed to identify effects of TNF alpha promoter polymorphisms on TDF treatment in CHB.

The limitations of our study were retrospective design. As the data of the patients were collected from patients' electronic files, data about the drug compliance of the patients, or side effects under treatments cannot be evaluated. This study is not designed to compare the efficacy of TDF to other drug choices.

This study is important for showing that at the end of 12 months four to fifth of the HBV patients had undetectable HBV DNA levels under TDF treatment. Keskin et al. showed efficacy of TDF at 135 CHB patients, our study was 117 CHB patients [20]. Our study includes high number of HBV patients under TDF in Turkey.

## CONCLUSION

Among patients with chronic HBV infection, TDF had satisfying antiviral efficacy. There is no primary resistance in patients treated with TDF. Patients had statistically significant improvement in AST, ALT, HBV DNA levels. Beside including the high number of TDF treated HBV patients in Turkey, HBsAg and HBeAg seroconversion was found to be lower than literature. Further and longer periods of researches were needed to evaluate the effects on seroconversion are needed.

## CONFLICT of INTEREST STATEMENT

The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the article.



## REFERENCES

- [1] Sarin S, Kumar M, Lau G, et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. *Hepatology international* 2016; 10(1): 1-98.
- [2] Yim HJ, Lok ASF. Natural history of chronic hepatitis B virus infection: what we knew in 1981 and what we know in 2005. *Hepatology* 2006;43: S173-S181.
- [3] McMahon BJ. Epidemiology and natural history of hepatitis B. *Seminars in liver disease* 2005;25(1):3-8.
- [4] Kumar M, Satapathy S, Monga R, et al. A randomized controlled trial of lamivudine to treat acute hepatitis B. *Hepatology* 2007;45(1):97-01.
- [5] Terrault NA, Lok AS, McMahon BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. *Hepatology* 2018;67(4):1560-99.
- [6] Chen C-J, Yang H-I, Su J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. *Jama* 2006;295(1):65-73.
- [7] Lok AS, McMahon BJ. Chronic hepatitis B. *Hepatology* 2007;45(2):507-39.
- [8] Chan HL, Fung S, Seto WK, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomized, double-blind, phase 3, non-inferiority trial. *The Lancet Gastroenterology & Hepatology* 2016;1(3):185-95.
- [9] Keeffe EB, Zeuzem S, Koff RS, et al. Report of an international workshop: roadmap for management of patients receiving oral therapy for chronic hepatitis B. *Clinical Gastroenterology and Hepatology* 2007;5(8):890-7.
- [10] ABIM laboratory test reference ranges. <https://www.abim.org/~media/ABIM%20Public/Files/pdf/exam/laboratory-reference-ranges.pdf> (Accessed January 2020)
- [11] Tang LS, Covert E, Wilson E, et al. Chronic Hepatitis B Infection: A Review. *Jama* 2018;319(17):1802-13.
- [12] Güzelbulut F, Ovünç A, Oetinkaya Z, et al. Comparison of the efficacy of entecavir and tenofovir in chronic hepatitis B. *Hepato-gastroenterology* 2012;59(114):477-80.
- [13] Başarir İ, İlikhan S, Soyaltın UE. Kronik aktif hepatit B tanılı hastalarımızın tedavi yanıtlarının değerlendirilmesi. *Akademik Gastroenteroloji Dergisi* 2013; 12(2):58-65.
- [14] Demir NA, Kölgelir S, Demir LS. Naif Kronik Hepatit B hastalarının Bir Yıllık 245 Mg/Gün Tenofovir Disoproksil Fumarate Tedavi Sonuçlarının Değerlendirilmesi. *Evaluation* 2013; 21:25.
- [15] Marcellin P, Heathcote EJ, Buti M, et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. *The New England journal of medicine* 2008;359(23):2442-55.
- [16] Woo G, Tomlinson G, Nishikawa Y, et al. Tenofovir and entecavir are the most effective antiviral agents for chronic hepatitis B: a systematic review and Bayesian meta-analysis. *Gastroenterology* 2010;139(4):1218-1229.
- [17] Terrault NA, Lok ASF, McMahon BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. *Hepatology* 2018; 67:1560
- [18] Buti M, Gane E, Seto WK, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomized, double-blind, phase 3, non-inferiority trial. *Lancet Gastroenterol Hepatol* 2016; 1:196.
- [19] İnkaya A, Türk Arıbaş e, Kandemir B, et al. Role of Tumor Necrosis Factor alpha promoter polymorphisms in interferon related side effects in chronic hepatitis B patients under interferon alpha 2b treatment. *Acta Medica* 2019; 50(2): 32 - 38.
- [20] Keskin O, Ormeci AC, Baran B, et al. Efficacy of tenofovir in adefovir-experienced patients compared with treatment-naive patients with chronic hepatitis B. *Antivir Ther.* 2014;19(6):543-50.

